
==== Front
Cancer Chemother Pharmacol
Cancer Chemother Pharmacol
Cancer Chemotherapy and Pharmacology
0344-5704
1432-0843
Springer Berlin Heidelberg Berlin/Heidelberg

37773538
4595
10.1007/s00280-023-04595-8
Correction
Correction to: An IQ consortium analysis of starting dose selection for oncology small molecule first‑in‑patient trials suggests an alternative NOAEL‑based method can be safe while reducing time to the recommended phase 2 dose
http://orcid.org/0000-0002-9691-6931
Jessen Bart A. bart.jessen@pfizer.com

1
Cornwell Paul 2
Redmond Sean 3
Visalli Thomas 4
Lemper Marie 5
Bunch Todd 6
Hart Timothy 7
1 grid.410513.2 0000 0000 8800 7493 Pfizer, Drug Safety Research and Development, San Diego, CA 92121 USA
2 grid.417540.3 0000 0000 2220 2544 Eli Lilly, Nonclinical Safety Assessment, Indianapolis, IN USA
3 grid.418152.b 0000 0004 0543 9493 Clinical Pharmacology & Safety Sciences, AstraZeneca Pharmaceuticals, Waltham, MA 02451 USA
4 grid.418767.b 0000 0004 0599 8842 Eisai Inc., Global Nonclinical Regulatory, Nutley, NJ 07110 USA
5 grid.432688.3 Development Science, UCB, Inc., Cambridge, MA 02140 USA
6 grid.419971.3 0000 0004 0374 8313 Nonclinical Safety Evaluation, Bristol Myers Squibb, Princeton, NJ 08540 USA
7 grid.418019.5 0000 0004 0393 4335 GlaxoSmithKline, IVIVT, Collegeville, PA 19426 USA
29 9 2023
29 9 2023
2024
94 3 11
© Springer-Verlag GmbH Germany, part of Springer Nature 2023
2023
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcCorrection to: Cancer Chemotherapy and Pharmacology 10.1007/s00280-023-04570-3

In the original publication, the Fig. 1b has been published incorrectly. The corrected Fig. 1b is given below:

The original article has been corrected.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Bart A. Jessen and Timothy Hart are co-chairs of the IQ DruSafe Working Group and equally contributing authors.
